Fetzer New CEO of Cerulean Pharma

Xconomy Boston — 

Oliver Fetzer has been named the new CEO of Cerulean Pharma, a Cambridge, MA-based developer of nanoparticle-based drugs for cancer and other diseases, according to the company. Fetzer, who was previously senior vice president of corporate development and R&D at Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:CBST), is taking over the chief executive post from veteran biotech executive and venture capitalist Alan Crane. Crane, who is the founding CEO of Cerulean and a venture partner at Polaris Venture Partners in Waltham, MA, has been named the biotech’s chairman of the board. Polaris is an investor in Cerulean.